Transglutaminase 2 Mediates the Cytotoxicity of Resveratrol in a Human Cholangiocarcinoma and Gallbladder Cancer Cell Lines

References

• Khan SA, Thomas HC, Davidson BR, and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366, 1303–1314, 2005. doi:10.1016/S0140-6736(05)67530-7.
   PubMed Web of Science ®Google Scholar
• Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, et al.: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37, 806–813, 2002. doi:10.1016/S0168-8278(02)00297-0.
   PubMed Web of Science ®Google Scholar
• Karlsen TH, Folseraas T, Thorburn D, and Vesterhus M: Primary sclerosing cholangitis – a comprehensive review. J Hepatol 67(6), 1298–1323, 2017. doi:10.1016/j.jhep.2017.07.022.
   Web of Science ®Google Scholar
• Alpini G, McGill JM, and Larusso NF: The pathobiology of biliary epithelia. Hepatology 35, 1256–1268, 2002. doi:10.1053/jhep.2002.33541.
   PubMed Web of Science ®Google Scholar
• Marcano-Bonilla L, Mohamed EA, Mounajjed T, and Roberts LR: Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. Chin Clin Oncol 5, 61, 2016. doi:10.21037/cco.2016.10.09.
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma KL, Gupta A, Yadav A, and Kumar A: Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol 23, 3978–3998, 2017. doi:10.3748/wjg.v23.i22.3978.
   PubMed Web of Science ®Google Scholar
• Langcake P and Pryce R: The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection injury. Physiological Plant Pathology 9, 77–86, 1976. doi:10.1016/0048-4059(76)90077-1.
   Google Scholar
• Bishayee A: Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila) 2, 409–418, 2009. doi:10.1158/1940-6207.CAPR-08-0160.
   PubMed Web of Science ®Google Scholar
• Shukla Y and Singh R: Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci 1215, 1–8, 2011. doi:10.1111/j.1749-6632.2010.05870.x.
   PubMed Web of Science ®Google Scholar
• Barger JL, Kayo T, Vann JM, Arias EB, Wang J, et al.: A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 3, e2264, 2008. doi:10.1371/journal.pone.0002264.
   PubMed Web of Science ®Google Scholar
• Baur JA and Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5, 493–506, 2006. doi:10.1038/nrd2060.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Yang LV, et al.: Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY) 9, 1477–1536, 2017.
   PubMedGoogle Scholar
• Roncoroni L, Elli L, Dolfini E, Erba E, Dogliotti E, et al.: Resveratrol inhibits cell growth in a human cholangiocarcinoma cell line. Liver Int 28, 1426–436, 2008. doi:10.1111/j.1478-3231.2008.01749.x.
   PubMed Web of Science ®Google Scholar
• Djordjevic B and Lange CS: Cell-cell interactions in spheroids maintained in suspension. Acta Oncol 45, 412–420, 2006. doi:10.1080/02841860500520743.
   PubMed Web of Science ®Google Scholar
• Dolfini E, Roncoroni L, Elli L, Fumagalli C, Colombo R, et al.: Cytoskeleton reorganization and ultrastructural damage induced by gliadin in a three-dimensional in vitro model. World J Gastroenterol 11, 7597–7601, 2005. doi:10.3748/wjg.v11.i48.7597.
   PubMed Web of Science ®Google Scholar
• Frampton GA, Lazcano EA, Li H, Mohamad A, and DeMorrow S: Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. Lab Invest 90, 1325–1338, 2010. doi:10.1038/labinvest.2010.99.
   PubMed Web of Science ®Google Scholar
• Sheng L, An L, He Y, Fan G, and Yuan Y: Research on resveratrol's effects on suppressing growth and inducing apoptosis of GBC cells. Zhong Yao Cai 28(6), 489–491, 2005.
   PubMedGoogle Scholar
• Fesus L, Thomazy V, and Falus A: Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett 224, 104–108, 1987. doi:10.1016/0014-5793(87)80430-1.
   PubMed Web of Science ®Google Scholar
• Meshram DD, Pike CVS, and Coussons PJ: Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy. Eur J Pharmacol 815, 332–342, 2017. doi:10.1016/j.ejphar.2017.09.035.
   PubMed Web of Science ®Google Scholar
• Szondy Z, Korponay-Szabó I, Király R, Sarang Z, and Tsay GJ: Transglutaminase 2 in human diseases. Biomedicine (Taipei) 7, 15, 2017. doi:10.1051/bmdcn/2017070315.
   PubMedGoogle Scholar
• Gissel H and Clausen T: Excitation-induced Ca2+ influx and skeletal muscle cell damage. Acta Physiol Scand 171, 327–334, 2001. doi:10.1046/j.1365-201x.2001.00835.x.
   PubMedGoogle Scholar
• Verma RS and Dosik H: Frequencies of centromeric heteromorphisms of human chromosomes 3 and 4 as detected by QFQ technique: can they be identified by RFA technique? Can J Genet Cytol 21, 109–113, 1979. doi:10.1139/g79-014.
   PubMedGoogle Scholar
• Strazzabosco M, Poci C, Spirlí C, Sartori L, Knuth A, et al.: Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line. Hepatology 19, 145–154, 1994.
   PubMed Web of Science ®Google Scholar
• Nussbaumer S, Bonnabry P, Veuthey JL, and Fleury-Souverain S: Analysis of anticancer drugs: a review. Talanta 85, 2265–2289, 2011. doi:10.1016/j.talanta.2011.08.034.
   PubMed Web of Science ®Google Scholar
• Monsuez JJ, Charniot JC, Vignat N, and Artigou JY: Cardiac side-effects of cancer chemotherapy. Int J Cardiol 144, 3–15, 2010. doi:10.1016/j.ijcard.2010.03.003.
   PubMed Web of Science ®Google Scholar
• Dropcho EJ: The neurologic side effects of chemotherapeutic agents. Continuum (Minneap Minn) 17, 95–112, 2011.
   PubMedGoogle Scholar
• Athar M, Back JH, Tang X, Kim KH, Kopelovich L, et al.: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224, 274–283, 2007. doi:10.1016/j.taap.2006.12.025.
   PubMed Web of Science ®Google Scholar
• Singh CK, George J, and Ahmad N: Resveratrol-based combinatorial strategies for cancer management. Ann N Y Acad Sci 1290, 113–121, 2013. doi:10.1111/nyas.12160.
   PubMed Web of Science ®Google Scholar
• Smoliga JM, Baur JA, and Hausenblas HA: Resveratrol and health–a comprehensive review of human clinical trials. Mol Nutr Food Res 55, 1129–1141, 2011. doi:10.1002/mnfr.201100143.
   PubMed Web of Science ®Google Scholar
• Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, et al.: Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70, 7392–7399, 2010. doi:10.1158/0008-5472.CAN-10-2027.
   PubMed Web of Science ®Google Scholar
• Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, et al.: Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases–safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 4, 1419–1425, 2011. doi:10.1158/1940-6207.CAPR-11-0148.
   PubMed Web of Science ®Google Scholar
• Kunz-Schughart LA: Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor. Cell Biol Int 23, 157–161, 1999. doi:10.1006/cbir.1999.0384.
   PubMed Web of Science ®Google Scholar
• Elli L, Ciulla MM, Busca G, Roncoroni L, Maioli C, et al.: Beneficial effects of treatment with transglutaminase inhibitor cystamine on the severity of inflammation in a rat model of inflammatory bowel disease. Lab Invest 91, 452–461, 2011. doi:10.1038/labinvest.2010.186.
   PubMed Web of Science ®Google Scholar
• Jang JH, Park JS, Lee TJ, and Kwon TK: Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis. Cancer Lett 287, 224–230, 2010. doi:10.1016/j.canlet.2009.06.013.
   PubMed Web of Science ®Google Scholar
• Freund KF, Doshi KP, Gaul SL, Claremon DA, Remy DC, et al.: Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 33, 10109–10119, 1994. doi:10.1021/bi00199a039.
   PubMed Web of Science ®Google Scholar
• Johnson KA, Polewski M, and Terkeltaub RA: Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res 102, 529–537, 2008. doi:10.1161/CIRCRESAHA.107.154260.
   PubMed Web of Science ®Google Scholar
• Siegel M and Khosla C: Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115, 232–45, 2007. doi:10.1016/j.pharmthera.2007.05.003.
   PubMed Web of Science ®Google Scholar
• Varoni EM, Lo Faro AF, Sharifi-Rad J, and Iriti M: Anticancer molecular mechanisms of resveratrol. Front Nutr 3, 8, 2016. doi:10.3389/fnut.2016.00008.
   PubMed Web of Science ®Google Scholar